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Buprenorphine Treatment for Young Adults 
Findings and Strategies from a 
NIDA Clinical Trials Network Study 
 
Background Information: NIDA/SAMHSA Blending Initiative 
The National Institute on Drug Abuse (NIDA) and the Substance Abuse and Mental Health 
Services Administration (SAMHSA) have created a partnership to disseminate information to the 
addiction treatment field.  Through the NIDA-SAMHSA Blending Initiative, special groups called 
Blending Teams meet to design dissemination strategies and develop research-based products.  
Members of these Blending Teams come from the NIDA-funded National Drug Abuse 
Treatment Clinical Trials Network (CTN) and the SAMHSA-funded Addiction Technology 
Transfer Center (ATTC) Network. 
 
In the year 1999, NIDA created the National Drug Abuse Treatment Clinical Trials Network 
(CTN).  The CTN conducts studies of behavioral, pharmacological, and integrated behavioral 
and pharmacological treatment interventions in rigorous, multi-site clinical trials to determine 
effectiveness across a broad range of community-based treatment settings and diverse patient 
populations.  As the CTN research is completed, NIDA researchers work with representatives 
from the ATTC network to provide the results and strategies for implementing these findings into 
clinical settings.  This will decrease the time it takes for research to be incorporated into 
treatment settings and will thereby to improve the quality of drug abuse treatment throughout 
the country. 
Focus on Buprenorphine 
In 2002, tablet formulations of buprenorphine were approved by the Food and Drug 
Administration (FDA) for the treatment of opiate addiction.  Additionally, the CTN completed 
several clinical trials related to specific uses of this medication.  One of these trials looked at 
strategies for medically-assisted withdrawal from opioids using buprenorphine with young 
adults.  This training presents the relevant background for the study as well as the procedures 
and results.  The training ends by examining the implications of the results of the study and how 
these results might shape the way that services are provided in real-world clinical settings. 
The Study Participants 
The CTN Trial allowed for recruitment of adolescents and young adults ages 14-21.  However, 
the number of participants under the age of 18 was very small (less than 18%).  This makes it 
impossible to generalize results to this age group.  Therefore, the implications for the study 
results will focus on the young adult population (ages 18-21).   
However, statistics and other background information will be presented for both adolescents 
and young adults.  In order to fully contextualize the nature of the problem, it is important to 
understand how adolescents are using opioids and how their use compares to the young adult 
population.  As information is presented, clear description of the population (i.e., adolescents 
ages 14-17, young adults ages 18-21, or both) being discussed will be made as the information 
is being presented during the training. 
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Blending Team Members 
 Thomas Freese, Ph.D. – Chair  – Pacific Southwest ATTC  
 Michael Bogenschutz, M.D. – CTN  Southwest Node 
 Thomas Durham, Ph.D. – Central East ATTC 
 Shannon Garrett, M.S.W., L.G.S.W., CSC-AD – CTP Mid-Atlantic Node 
 Laura McNicholas, M.D., Ph.D. – CTN Delaware Valley Node 
 Beth Rutkowski, M.P.H. – Pacific Southwest ATTC 
 Susan Storti, Ph.D., R.N. – Synergy Enterprises, Inc. 
 Geetha Subramaniam, M.D. – CTN Mid-Atlantic Node 
 Pamela Waters, M.Ed., C.A.C., C.P.P. – Southern Coast  ATTC 
 
What Does the Training Package Contain? 
 PowerPoint Training Slides 
 Trainer’s Guide with detailed instructions for how to convey the information and conduct the 
interactive exercises. 
 
What Does This Trainer’s Manual Contain? 
The objectives of this Module are to: 
1) Provide a brief overview of opioid use among adolescents and young adults;  
2) Describe the procedures and results of a NIDA CTN trial examining use of buprenorphine 
among young adults; and 
3) Explore the meaning and implications of these results for treating adolescents in real-world 
settings.  
 
This Module can be used as a stand-alone training of approximately 3 hours in length or can be 
added to the larger Buprenorphine Awareness training to focus additional attention on treatment 
of young adults.  
 
The notes below contain information that can be presented with each slide.  This information is 
designed as a guidepost and can be adapted to meet the needs of the local training situation.  
Information can be added or deleted at the discretion of the trainer(s). 
 
How Are the PowerPoint Training Slides Organized? 
For this manual, text that is shown in bold italics is a “Note to the Trainer.”  Text that is shown 
in normal font relates to the “Trainer’s Script” for the slide. 
 
It is important to note that almost every slide in this training contains some animation.  
Animations are used to call attention to particular aspects of the information or to present the 
information in a stepwise fashion to facilitate both the presentation of information and participant 
understanding.  Because of this, some information is hidden when slides first appear on the 
screen and then comes in as the slide is advanced.  No special notes are made if the animation 
simply causes the next row of text to appear.  However, when the animations are complex, step 
by step instructions are provided. 
 
General Information about Conducting the Training 
The training is designed to be conducted in small- to medium-sized groups (10-25 people).  It is 
possible to use these materials with larger groups, but the trainer will have to adapt the small 
group exercises to ensure that there is adequate time to cover all of the material. 
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Materials Needed to Conduct the Training 
 Computer with PowerPoint software installed (2003 or higher version) and LCD projector to 
project the PowerPoint training slides 
 Flip chart paper and easel/white board, and pens to write down relevant information 
 Prepared materials for Number Line Exercise (slide 34) and Gallery Walk (slides 81-83) 
  
Overall Training Notes 
It is critical that, prior to conducting an actual training, the trainer practice using this guide while 
showing the slide presentation in Slideshow Mode in order to be prepared to use the slides in 
the most effective manner. 
 
 
Note to speaker      Activity 
 
References  
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Buprenorphine Treatment: 
A Training for Multidisciplinary Addiction Professionals 
 
 
 
Combining the Presentations 
The NIDA/SAMHSA Blending Initiative has developed a suite of products on buprenorphine. 
The Buprenorphine Suite includes the following training curricula: 
 Buprenorphine Treatment: A Training for Multidisciplinary Addiction Professionals 
 Short Term Opioid Withdrawal Using Buprenorphine: Findings and Strategies From a 
NIDA Clinical Trials Network Study 
 Buprenorphine Treatment for Young Adults: Findings and Strategies From a NIDA 
Clinical Trials Network Study 
Each of these curricula is a self-contained training package that can be used to conduct a 
stand-alone training program. However, the Blending Team recognized that in many instances 
trainers may want to incorporate elements of two or all three curricula into a single training 
experience. Combining slides from the presentations may therefore be necessary. Below are 
instructions for combining slides for both PowerPoint 2007 and PowerPoint 1997-2003. 
PowerPoint 2007  
To combine slides into a single presentation, open all presentations from which you will be 
drawing slides. Determine which document will be the master document into which slides from 
the other presentation(s) will be copied. For instance, if you are conducting the Buprenorphine 
Treatment: A Training for Multidisciplinary Addiction Professionals, this would be your master 
document. It is recommended that you save a new copy of this presentation before altering it in 
order to preserve the original training content.
 
I.  Save a new copy of your presentation.  
(1) Click on the program icon in the upper right 
corner of your screen and then (2) click  
on Save As from the drop down menu. Next, (3) 
click on PowerPoint Presentation. A dialogue box 
will appear that will allow you to give the 
presentation a name and location.  
Click in this order: 
1. Program Icon 
2. Save As 
3. PowerPoint Presentation  
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II. Open the presentation from which slides will be copied. 
III. Select Slide Sorter view. 
Go to the Slide Sorter view by (1) clicking on View from the menu at the top of the page and 
then (2) clicking Slide Sorter located on the left side of the page near the top.  
 
 
IV. Select the slides to be copied. 
Slides can be copied in two ways. You can select all slides in the presentation, or you can 
choose only certain slides to copy. Instructions for each are presented below 
Select all slides in presentation. Copy all slides in the presentation by (1) clicking on Home 
from the menu at the top of the page and then (2) clicking on Select on the far right side of the 
page near the top. Next, (3) click on Select All from the drop down menu. All slides in the 
presentation will be highlighted in yellow. 
 
 
 
 
Finally, (4) copy the selected slides to the clipboard by clicking on Copy on the upper left of 
the screen. 
Click in this 
order:  
1. View 
2. Slide Sorter 
Click in this order:  
1. Home     2. Select     3. Select All 
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Select specific slides to copy. To copy only 
certain slides (rather than all of them), on your 
computer keyboard, hold down the control (Ctrl) 
button. While holding down Ctrl, click on the 
slides that you want to copy into the combined 
presentation. Only  slides on which you click will 
be selected (highlighted in yellow). In the close-
up example on the right, Slides 1 and 6 are 
selected (have a yellow box around them). 
Slides 2 and 5 are not selected. 
Once you have clicked on all the slides that you 
want to select, let go of the Ctrl key and then 
click on Copy on the upper left side of the page.   
Note: You may want to practice copying a 
few slides at a time until you are comfortable 
with this procedure. 
 
 
V.  Paste the copied slides into your 
presentation. 
Open your master presentation (the presentation into which the slides are to be copied).  Again 
go to the Slide Sorter view as described in Step III above. (1) Click in the space between the 
slides where you would like the 
copied slides to appear. A flashing 
line will appear between the slides. 
In this example, the copied slides 
will appear after Slide 18. Then (2) 
click on Paste in the upper left 
corner. 
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VI. Maintain original formatting. 
When copying slides from one presentation to the other, the formatting of the copied slides will 
be altered to match the presentation into which they are inserted. However, this often leads to 
significant formatting irregularities. In the example below, Slides 4 to 6 were inserted using the 
method described above. Notice that some of the text is too dark and difficult to read with the 
new formatting. 
 
To prevent this problem, it is recommended that the inserted slides maintain the formatting of 
the original presentation. The following steps show how to do this. 
After pasting the slides into the presentation, you will notice that a small clipboard appears near 
the last inserted slides.   
(1) Click on the clipboard and then (2) click on Keep Source Formatting in the drop-
down menu that appears. 
 
 
 
 
 
 
 
 
 
 
 
This will restore the formatting from the original presentation and ensure that the slides are 
legible when projected during a training session. 
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PowerPoint 1997-2003  
To combine slides into a single presentation, open all presentations from which you will be 
drawing slides. Determine which document will be the master document into which slides from 
the other presentations will be copied. For instance, if you are conducting the Buprenorphine 
Treatment: A Training for Multidisciplinary Addiction Professionals, this would be your master 
document. It is recommended that you save a new copy of this presentation before altering it in 
order to preserve the original training content. 
I.  Save a new copy of your presentation.  
(1) Click on the File button in the upper left corner of the toolbar and then (2) click  
on Save As from the drop-down menu. A dialogue box will appear that will allow you to 
give the presentation a name and location.  
 Click in this order:  
1. File 
2. Save As 
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II. Open the presentation from which slides will be copied. 
 
III. Select Slide Sorter view. 
Go to the Slide Sorter view by (1) clicking on View from the menu at the top of the page and 
then (2) clicking Slide Sorter from the drop-down menu.  
 
 
 
 
IV. Select the slides to be copied. 
Slides can be copied in two ways. You can select all slides in the presentation, or you can 
choose only certain slides to copy. Instructions for each are presented below. 
Click in this 
order:  
1. View 
2. Slide Sorter 
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Select all slides in presentation. Copy all slides in the presentation by (1) clicking on Edit in 
the top toolbar and then (2) clicking Select All from the drop-down menu. All slides in the 
presentation will be highlighted in dark blue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Finally, (3) click on the Edit button in the top toolbar and then click on Copy from the drop-down 
list. 
 
Select specific slides for copying. To copy 
only certain slides (rather than all of them), on 
your computer keyboard, hold down the control 
(Ctrl) button. While holding down Ctrl, click on 
the slides that you want to copy into the 
combined presentation. Only slides on which you 
click will be selected (highlighted in dark blue). In 
the close-up example on the right, Slides 3 and 6 
are selected (have a dark blue border around 
them). Once you have clicked on all the slides 
that you want to select, let go of the Ctrl key and 
then click on the Edit button in the top toolbar 
and then click on Copy from the drop-down 
menu.   
 
Note: You may want to practice copying a few 
slides at a time until you are comfortable with 
this procedure. 
 
V.  Paste the copied slides into your presentation. 
Open your master presentation (the presentation into which the slides are to be copied).  Again 
go to the Slide Sorter View as described in Step III above. (1) Click in the space between the 
slides where you would like the copied slides to appear. A flashing line will appear between the 
Click in this order:  
1. Edit  
2. Select All 
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slides. In this example, the copied slides will appear after Slide 6. Then (2) click on Edit and 
then Paste in the upper left corner. 
 
 
 
 
Click in space where 
slides are to be inserted. 
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VI. Maintain original formatting. 
When copying slides from one presentation to the other, the formatting of the copied slides will 
be altered to match the presentation into which they are inserted. However, this often leads to 
significant formatting irregularities. In the example below, Slides 7 to 9 were inserted into this 
presentation using the method described above. Notice that some of the text is too dark and 
difficult to read with the new formatting. 
 
 
To prevent this problem, it is recommended that the inserted slides maintain the formatting of 
the original presentation. The following steps will show you how to do this. 
After pasting the slides into the presentation, you will notice that a small clipboard appears near 
the last inserted slide.   
(1) Click on the 
clipboard and 
then (2) click on 
Keep Source 
Formatting in 
the drop-down 
menu that 
appears. 
This will restore 
the formatting 
from the original 
presentation 
and ensure that 
the slides are 
legible when 
projected during 
a training 
session. 
 
Three slides 
copied 
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Buprenorphine Treatment for Young Adults 
Slide-By-Slide Trainer Notes 
 
The notes below contain information that can be presented with each slide.  This 
information is designed as a guidepost and can be adapted to meet the needs of the 
local training situation.  Information can be added or deleted at the discretion of the 
trainer(s). 
 
 
 
Slide 1:  Title Slide 
 
Welcome participants and take care of housekeeping 
details such as location of restrooms, turning off cell 
phones, participate actively, etc. 
 
Briefly describe the development of the Blending Team 
product, as well as the purpose of the training as 
described in the introduction to this manual. 
 
It is important to note that this training is introductory and 
is focused on building awareness and encouraging 
multidisciplinary addiction professionals to learn more 
about buprenorphine and its role in opioid treatment. It is 
NOT designed to provide an expert level of competency in 
utilizing buprenorphine for the treatment of opioid 
addiction. 
 
Reiterate that throughout the training, the term “patient” 
has been used to refer to the individual seeking 
treatment. This terminology reflects the medicalized 
nature of buprenorphine treatment and underscores the 
fact that the treatment is largely physician-driven. The use 
of this term may be inconsistent with the vocabulary in 
common usage in the addiction treatment setting. 
 
Slide 1 
 
 
 
Slide 2:  NIDA/SAMHSA Blending Initiative 
 
Share the definition of “blend” based upon the Webster 
dictionary. 
 
Reference: 
 
blend. (2010). In Merriam-Webster Online Dictionary. Retrieved March 16, 
2010, from http://www.merriam-webster.com/dictionary/blend 
 
Slide 2 
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Slide 3:  NIDA/SAMHSA Blending Initiative 
 
Developed in 2001 by the National Institute on Drug Abuse 
(NIDA) and the Substance Abuse and Mental Health Services 
Administration’s (SAMHSA) Center for Substance Abuse 
Treatment, the NIDA/SAMHSA Blending Initiative is 
designed to meld science and practice together to improve 
substance use disorder treatment. The primary goal of this 
initiative is to disseminate research findings that will 
accelerate the adoption and implementation of research-
based drug abuse treatment into community-based practice.  
 
Blending Products are designed to shorten the time that it 
takes scientific findings to become available in a usable way 
for frontline service providers. This is imperative for successful 
outcomes of clients in addiction treatment programs 
throughout the country. 
 
Slide 3 
 
Slide 4:  Blending Team Members 
 
Blending Teams are composed of NIDA-funded researchers, 
community-based substance abuse treatment practitioners 
and trainers from SAMHSA's Addiction Technology Transfer 
Center (ATTC) Network who work closely together to develop 
the NIDA/SAMHSA Blending products.  
 
Note to the Trainer(s):  Acknowledge the members of the 
Blending Team who created this module. Note that the 
membership consisted of four ATTC representatives and four 
NIDA-funded researchers and community treatment providers. 
 
Slide 4 
 
 
 
 
 
 
 
 
 
Slide 5:  Objectives for the Training 
 
There are four primary objectives for this training: 
 To define the prevalence of and treatment admission 
rates for non-medical use of opioids among young adults 
 To describe the mechanism of action of buprenorphine/ 
naloxone  
 To explore and increase understanding of the results of 
new research on using buprenorphine to treat opioid 
addiction in young adults 
 To describe the implications of these findings for the 
treatment of opioid addiction in young adults 
 
Slide 5 
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Slide 6:  Introductions 
 
For smaller groups (20 or less): Begin the training by 
asking participants to briefly introduce themselves by 
providing their name and the agency for which they work, 
their experience with opioid treatment, and what they 
expect to gain from the training.  
 
For larger groups:  Personal introductions will take too 
much time to complete.  Omit this slide and proceed by 
asking people to identify their role in the treatment 
system by raising their hand.   
 
At minimum, ask: 
Who is: 
 A direct treatment provider 
 A counselor 
 A nurse 
 A physician 
 A social worker 
 An administrator 
 An educator 
 Anyone that I missed? 
 
Slide 6 
 
 
 
Slide 7:  So who are the participants in this endeavor?  
  
So now we will introduce the key participants who helped put 
these materials together. 
 
Slide 7 
 
Slide 8:  An Introduction to SAMHSA/CSAT  
 
The Center for Substance Abuse Treatment (CSAT) of the 
Substance Abuse and Mental Health Services Administration 
(SAMHSA), U.S. Department of Health and Human Services 
(DHHS), was created in October 1992 with a congressional 
mandate to expand the availability of effective treatment and 
recovery services for alcohol and drug problems. 
 
Slide 8 
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Slide 9:  SAMHSA/CSAT  
 
Read CSAT mission.    
 
Note to the Trainer(s):  Highlight the importance of the 
research base in all of CSAT’s programming and educating 
the field about the advances of science to continually improve 
the quality of services provided.  
 
Slide 9 
 
 
 
 
 
Slide 10:  The ATTC Network  
 
One of the major vehicles that SAMHSA has for ensuring that 
the workforce is adequately trained is the Addiction 
Technology Transfer Center (ATTC) Network. 
Slide 10 
 
Slide 11:  The ATTC Network  
 
Fourteen regional Centers and a National Office comprise the 
ATTC Network, which is dedicated to identifying and 
advancing opportunities for improving addiction treatment.   
  
The vision of the ATTC Network is to unify science, 
education and services to transform the lives of individuals 
and families affected by alcohol and other drug addiction.   
  
Serving the 50 United States, the District of Columbia, 
Puerto Rico, the U.S. Virgin Islands and the Pacific Islands, 
the ATTC Network delivers cutting-edge knowledge and 
skills that develop a powerful workforce.  
  
Slide 11 
 
Slide 12:  An Introduction to the National Institute on Drug 
Abuse  
 
The National Institute on Drug Abuse (NIDA) was established 
in 1974, and in October 1992 it became part of the National 
Institutes of Health, Department of Health and Human 
Services.   
  
Recent scientific advances have revolutionized our 
understanding of drug abuse and addiction. The majority of 
these advances, which have dramatic implications for how to 
best prevent and treat addiction, have been supported by the 
National Institute on Drug Abuse (NIDA). 
  
Slide 12 
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Slide 13:  The  Mission of NIDA 
 
NIDA is not only seizing upon unprecedented opportunities 
and technologies to further the understanding of how drugs of 
abuse affect the brain and behavior, but also working to 
ensure the rapid and effective transfer of scientific data to 
policy makers, drug abuse practitioners, other health care 
practitioners, and the general public. The scientific knowledge 
that is generated through NIDA-funded research is a critical 
element to improving the overall health of the Nation. The goal 
of NIDA is to ensure that science, not ideology or anecdote, 
forms the foundation for all of our Nation's drug abuse 
reduction efforts. 
  
Slide 13 
 
Slide 14:  So what is this thing called the CTN?  
 
To date, the efficacy of new treatments for drug addiction has 
been demonstrated primarily in specialized research settings, 
with somewhat restricted patient populations. This presents a 
problem when trying to apply these findings about new 
treatments into community-based treatment programs, which 
typically serve diverse populations.  To address this problem, 
the National Institute on Drug Abuse (NIDA) established the 
National Drug Abuse Treatment Clinical Trials Network (CTN). 
 
Slide 14 
 
Slide 15:  NIDA’s Clinical Trials Network  
 
The mission of the CTN is twofold:  
 Conduct studies of behavioral, pharmacological, and 
integrated behavioral and pharmacological interventions 
to determine therapeutic effect in rigorous, multisite 
clinical trials to determine effectiveness across a broad 
range of community-based treatment settings and 
diversified patient populations; and  
 Transfer the research results to physicians, providers, and 
their patients to improve the quality of drug abuse 
treatment throughout the country using science as the 
vehicle.  
 
Slide 15 
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Slide 16:  CTN Node  
 
The CTN is comprised of Nodes that are dispersed across the 
country.   Each Node has one Regional Research Training 
Center (RRTC) and 5 – 10 affiliated community treatment 
programs (CTP).  CTN research is conducted in the CTPs.  
CTPs are chosen to participate in a given research protocol 
based on match between the study questions and 
requirements and the populations served by the CTP.  For 
instance, in the buprenorphine studies, a CTP could be 
chosen if they served an opioid dependent population from 
whom they could recruit study participants.  
 
Slide 16 
 
Slide 17:  Why Focus on Young Adults 
 
Many social and developmental changes take place during 
adolescence and into young adulthood. Social and parental 
control lessens during this period, and young people become 
freer to choose behaviors (for example, drug use or heavy 
drinking) and lifestyles that are not constrained by others. 
Because some emerging adults will maintain or increase their 
problematic drug or alcohol use over time (rather than mature 
out of such use and related problems), it is important to 
intervene effectively before they develop long-lasting drug use 
patterns or disorders. 
 
Slide 17 
 
Slide 18:  The Brain Undergoes Tremendous Change 
 
It is common knowledge that the brain undergoes tremendous 
changes early in development.  This slide shows increases in 
activity across the brain during the first year after birth.  The 
more red exhibited, the more activity is seen in that area. 
 
Reference: 
 
NIDA.  (2007). Drugs Brains, and Behavior:  The Science of Addiction (NIH 
Pub No. 07-5605).  Downloaded from 
http://www.drugabuse.gov/ScienceofAddi 
 
Slide 18 
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Slide 19:  Continuing Brain Development for Adolescents 
and Young Adults 
 
Substantial changes continue throughout adolescence and 
into young adulthood.  Early in childhood, the brain produces 
an extremely large number of connections across the brain, 
many more than will be needed later in adulthood. 
 
During adolescence and young adulthood, the brain 
strengthens important connections. 
 
At the same time, it eliminates and shapes connections to 
increase efficiency.  The pruning of neurons occurs from the 
back of the brain to the front of the brain, so that frontal lobes 
are the last to fully form. 
 
Reference: 
 
Gogtay, N., et. al. (2004). Dynamic mapping of human cortical development 
during childhood through early adulthood.  Proceedings of the National 
Academy of Sciences, 101, 8174-8179. 
 
Slide 19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Slide 20:  Continuing Brain Development 
 
This drawing illustrates the pruning process.   
 
Move forward to reveal first picture 
Between birth and 6 years of age… 
 
Move forward to reveal second picture 
…there is a tremendous proliferation of neural connections.  
 
Move forward to reveal final  picture 
This is followed by sustained thinning starting around 
puberty. Scientists think this process reflects greater 
organization of the brain as it prunes redundant connections, 
and increases in myelin, which enhance transmission of 
brain messages. 
 
Reference: 
 
Shore, R. (1997). Rethinking the brain. New York: Families and Work 
Institute. 
 
Slide 20 
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Slide 21:  Brain Development, Ages 5 - 20 Years 
 
Important note on this slide: 
This slide has complex animations and the trainer should 
practice prior to training.  A step-by-step guide is 
provided below. 
 
The first bullet comes in automatically at the beginning of 
the slide.  Provide the following description: 
 This slide demonstrates the neural pruning through 
animations.  This is a series of MRI scans from healthy 
children showing brain development as they age from 5 to 
20 years. 
 
Move forward to reveal the next bullet, and present the 
information: 
 Red indicates more gray matter and blue indicates less 
gray matter. 
 
Move forward and a small brain image will briefly appear 
on the lower right and then a short movie will 
automatically play full screen showing brain maturation.  
Once it stops, the small image of the brain will appear 
again on the lower right of the slide.  Move forward to 
reveal the next bullet: 
 As you can see, the pruning occurs from the back of the 
brain toward the front. 
 
Move forward to reveal the last bullet: 
 This means that the prefrontal cortex (responsible for 
executive functioning, like decision-making) is the last to 
mature. 
 
Point out that the animation is replaying so that people 
can see it again.  A static image of the progression will 
appear on the lower left as well.  When people have had 
time to observe, move forward to next slide. 
 
References: 
 
NIDA.  (2007). Drugs Brains, and Behavior:  The Science of Addiction (NIH 
Pub No. 07-5605).  Downloaded from 
http://www.drugabuse.gov/ScienceofAddiction. 
 
Gogtay, N., et. al. (2004). Dynamic mapping of human cortical development 
during childhood through early adulthood.  Proceedings of the National 
Academy of Sciences, 101, 8174-8179 
 
Slide 21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Buprenorphine Treatment for Young Adults Training Manual   Page 23 
 
 
Slide 22:  The interaction between the developing nervous 
system and drugs of abuse can contribute to: 
 
In reality, the exact impact of substance use on the developing 
brain is not known.  However, when we look at the impact on 
the adult brain and understand normal development, several 
things seems true about this interaction, including that it may 
lead to difficulties in decision making and understanding the 
consequences of behavior (Fiellin, 2008). Additionally, it may 
increase the risk of memory and attention problems. 
 
These impairments, in turn, may lead to increased 
experimentation across a variety of behaviors; and increase 
the risk of addiction to a variety of substances (Fiellin, 2008). 
 
Reference: 
 
Fiellin, D. A. (2008).  Treatment of adolescent opioid dependence: No quick 
fix. Journal of the American Medical Association, 300(17), 2057-2059. 
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Slide 23:  Young Brains are Different from Older Brains 
 
The brain continues to develop into adulthood and undergoes 
dramatic changes during adolescence.  This means that 
young brains are different from older brains. One example of 
this difference is evidenced by the fact that adolescent rats 
are: 
 more susceptible to the effects of alcohol on memory 
and learning, but 
 less susceptible to the motor and sedative effects. 
 
These factors may combine to increase the vulnerability to 
substance dependence in adolescents and young adults. 
 
Reference: 
 
Hiller-Sturmhofel, S., & Swartzwelder, H. S. (2004/2005). Alcohol’s effects 
on the adolescent brain: What can be learned from animal models. Alcohol 
Research & Health, 28(4), 213-221. 
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Slide 24:  Why Focus on Young Adults? 
 
Young adults have been shown to have increased vulnerability 
to, and the potential for increased problems from, substance 
use.  The next series of slides will look specifically at 
prevalence of opioid use in this population. 
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Slide 25:  Prevalence of Use 
 
Recent concern has focused on opioid use among 
adolescents and young adults.  Rates of heroin use are on the 
downturn among youth, however the rates of non-medical use 
of opioids have been steadily increasing. 
 
The annual prevalence of heroin use among youth rose in the 
mid- and late 1990s, reaching peak levels in 1996 among 8th 
graders (1.6%), in 1997 among 10th graders (1.4%), and in 
2000 among 12th graders (1.5%).  Since those peak levels, 
heroin use has declined among students in all three grade 
levels to 0.7-.09% (Johnston, O’Malley, Bachman, and 
Schulenberg, 2009). 
 
However, for the general population over 12 years of age, 
recent data show that 13.4% of individuals who reported new 
use of heroin in the past 13 to 24 months meet criteria for 
substance dependence (SAMHSA, OAS, 2008). 
 
References: 
 
Johnston, L. D., O'Malley, P. M., Bachman, J. G., & Schulenberg, J. E. 
(2009). Monitoring the Future national survey results on drug use, 1975-
2008. Volume I: Secondary school students (NIH Publication No. 09-7402). 
Bethesda, MD: National Institute on Drug Abuse.  
  
Substance Abuse and Mental Health Services Administration, Office of 
Applied Studies. (February 5, 2009). The NSDUH Report: Trends in 
Nonmedical Use of Prescription Pain Relievers: 2002 to 2007. Rockville, 
MD. 
 
Substance Abuse and Mental Health Services Administration, Office of 
Applied Studies. (March 27, 2008). The NSDUH Report: Substance Use and 
Dependence Following Initiation Following Alcohol or Illicit Drug Use. 
Rockville, MD. 
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Slide 26:  Non-Medical Pain Reliever Use in the Past Year 
Among Persons Aged 12 or Older 
Percentages, Annual Averages Based on 2004, 2005, and 
2006 National Survey on Drug Use and Health (NSDUH) 
 
Move forward to reveal first animation 
Data indicate that past year non-medical use of pain 
relievers ranged from a low of 2.48 percent in a ward of the 
District of Columbia… 
 
Move forward to reveal next animation 
…to a high of 7.92 percent in northwest Florida. 
 
Move forward to reveal next animation 
 Of the 15 substate regions with the highest rates of 
nonmedical use of pain relievers, 10 substate regions 
were in southern States and 5 were in western States  
 
Move forward to reveal next animation 
 Of the 15 substate regions with the lowest rates of 
nonmedical use of pain relievers, 7 substate regions were 
in southern States, 4 were in midwestern States, 3 were 
in northeastern States, and 1 was in a western State. 
 
Reference: 
 
Substance Abuse and Mental Health Services Administration, Office of 
Applied Studies. (June 19, 2008). The NSDUH Report -- Nonmedical Use of 
Pain Relievers in Substate Regions: 2004 to 2006. Rockville, MD. 
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Slide 27:  Rates of Current Heroin Use 
 
Drug prevalence data from multiple National Surveys on Drug 
Use and Health (SAMHSA, 2009) indicate that rates of use for 
heroin have been stable or have declined for most age 
groups. These data show that past year rates of heroin use 
did not significantly change in any measured age group during 
that same period, except 18-25 year olds, where the 2008 
estimate was significantly higher than the 2003 estimate, with 
the highest level of usage among young adults aged 18-25 
(SAMHSA, 2009). 
 
Additional Information  for the Trainer(s): 
 
The National Drug Intelligence Center (US Department of 
Justice) reports that although heroin use is stable, it could 
increase as more prescription narcotic abusers switch to 
heroin. Officials who were surveyed in treatment facilities 
throughout the country reported that many abusers of 
prescription opiates, such as OxyContin, Percocet, and 
Vicodin, eventually begin abusing heroin because it is typically 
cheaper and easier to obtain, and it provides a more intense 
high. Treatment officials also reported that once an individual 
switches from prescription opiates to heroin, he or she rarely 
switches back to exclusively abusing prescription opiates 
(National Drug Intelligence Center, 2007).  
 
References: 
 
Substance Abuse and Mental Health Services Administration. (2009). 
Results from the 2008 National Survey on Drug Use and Health: National 
Findings (Office of Applied Studies, NSDUH Series H-36, HHS Publication 
No. SMA 09-4434). Rockville, MD. 
 
National Drug Intelligence Center. (2007). National Drug Threat Assessment 
2008.  (Document ID: 2007-Q0317-003).  Washington, DC: U.S. Department 
of Justice 
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Slide 28:  Non-Medical Use of Prescription Drugs 
 
Data for adolescents and young adults is hidden to focus 
attention on adults (26+) and all populations aged 12 and 
older 
According to the 2008 National Survey on Drug Use and 
Health, the percent of U.S. household population aged 12 
and older reporting past month non-medical use of various 
psychotherapeutic medications is shown in the table.   
 
Move forward to reveal data for adolescents and young 
adults 
Opiate drugs show the highest prevalence in this 
classification with the highest rates of use among young 
adults aged 18-25; pain relievers were the most abused 
prescription drugs overall. 
 
Reference: 
 
Substance Abuse and Mental Health Services Administration. (2009). 
Results from the 2008 National Survey on Drug Use and Health: National 
Findings (Office of Applied Studies, NSDUH Series H-36, HHS Publication 
No. SMA 09-4434). Rockville, MD. 
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Slide 29:  New Non-Medical Users of Pain Relievers 
 
Data from the 2008 NSDUH show that 2.2 million people, 
aged 12 or older, initiated nonmedical use of prescription pain 
relievers within the past year. This averages to approximately 
6,000 initiates (new users) per day (SAMHSA, 2009).  
 
Among youth aged 12 to 17, females were more likely than 
males to have used pain relievers non-medically in the past 
year, whereas males aged 18 to 25 and males aged 26 to 34 
had higher rates than their female counterparts (SAMHSA, 
OAS, 2007).   
 
Emergency room data from the Drug Abuse Warning Network 
(DAWN) (SAMHSA, 2008) showed that emergency 
department visits involving hydrocodone/combinations 
increased 44% and oxycodone/combinations increased 56% 
from 2004 to 2006. 
 
References: 
 
Substance Abuse and Mental Health Services Administration. (2009). 
Results from the 2008 National Survey on Drug Use and Health: National 
Findings (Office of Applied Studies, NSDUH Series H-36, HHS Publication 
No. SMA 09-4434). Rockville, MD. 
 
Substance Abuse and Mental Health Services Administration, Office of 
Applied Studies. (April 6, 2007). The NSDUH Report: Patterns and Trends in 
Nonmedical Prescription Pain Reliever Use: 2002 to 2005. Rockville, MD. 
 
Substance Abuse and Mental Health Services Administration, Office of 
Applied Studies.  Drug Abuse Warning Network, 2006: National Estimates of 
Drug-Related Emergency Department Visits. DAWN Series D-30, DHHS 
Publication No. (SMA) 08-4339, Rockville, MD, 2008. 
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Slide 30:  Lifetime Non-medical Use of Pain Relievers 
Among Young Adults 
 
Data is hidden to focus attention on the question for 
discussion.  After orienting people to the slide ask the 
question: 
“Which of these substances do you think is most prevalent 
among young adult users?” 
 
Move forward to reveal data: 
The rates of past year nonmedical use of pain relievers are 
even more alarming when you compare these rates with 
those from just five short years ago.   
 
Reference: 
 
Substance Abuse and Mental Health Services Administration, Office of 
Applied Studies (2008). Results from the 2007 National Survey on Drug Use 
and Health: National Findings (NSDUH Series H-34, DHHS Publication 
No. SMA 08-4343). Rockville, MD. 
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Slide 31:  Other National Data Sources  
 
The 2008 Monitoring the Future Survey indicated a continuing 
high rate of prescription drug abuse among teens, with little 
change seen in the past six years. Nearly 10% of high school 
seniors reported past year nonmedical use of Vicodin, and 
4.7% report abusing OxyContin, both powerful opioid 
painkillers (Johnston et al., 2009).  
 
Treatment facilities also report higher rates of admittance by 
abusers of other opiates/synthetics. According to the 
Treatment Episode Data Set (TEDS), between 1997 and 
2007, treatment admissions for abuse of other 
opiates/synthetics grew more than 450% (SAMHSA, OAS, 
2009).  
 
References: 
 
Johnston, L. D., O’Malley, P. M., Bachman, J. G., & Schulenberg, J. E. 
(2009). Monitoring the Future national results on adolescent drug use: 
Overview of key findings, 2008 (NIH Publication No. 09-7401). 
Bethesda, MD: National Institute on Drug Abuse. 
 
Substance Abuse and Mental Health Services Administration, Office of 
Applied Studies. Treatment Episode Data Set (TEDS). Highlights - 2007. 
National Admissions to Substance Abuse Treatment Services, DASIS 
Series: S-45, DHHS Publication No. (SMA) 09-4360, Rockville, MD, 2009. 
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Slide 32:  National Treatment Admissions for Heroin and 
Other Opiates in 2007 
 
The Treatment Episode Data Set (TEDS) also reports that 
from 1997 to 2007, the number of persons who were admitted 
to treatment programs across the U.S. with a primary problem 
with opiates other than heroin increased from 16,274 to 
90,516 (SAMHSA, OAS, 2009). The table shows the “primary 
drug” data for treatment admissions in 2007 by age breakouts 
for adolescents and young adults. Of the age categories 
shown on this slide, the highest percentage of treatment 
admissions are among young adults aged 20 to 24 for both 
heroin (14.5%) and other opiates (21.8%). 
 
Reference: 
 
Substance Abuse and Mental Health Services Administration, Office of 
Applied Studies. Treatment Episode Data Set (TEDS). Highlights - 2007. 
National Admissions to Substance Abuse Treatment Services, DASIS 
Series: S-45, DHHS Publication No. (SMA) 09-4360, Rockville, MD, 2009. 
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Slide 33:  Treatment for Opioid Addiction 
 
The usual treatment for opioid-addicted young adults is short-
term detoxification and individual or group therapy in 
residential or outpatient settings over weeks or months.  
Clinicians report that relapse is high, yet many programs 
remain committed to this approach.  Other than treating 
withdrawal, most programs do not use agonist medication, 
such as buprenorphine. 
 
Many clinicians believe that buprenorphine is a medication for 
adults.  However, buprenorphine is FDA-approved for 
treatment of individuals age 16 and older. Recent studies have 
been completed on the use of buprenorphine on this young 
population. 
 
The National Institute on Drug Abuse (NIDA) undertook a 
study in six sites within the CTN.  Because of the dangers 
associated with untreated opioid addiction, the commitment of 
programs treating opioid-addicted youth with non-medication 
therapies, and favorable results using buprenorphine in other 
studies, the CTN conducted a randomized trial of extended 
treatment including the use of buprenorphine versus the usual 
short-term detoxification among opioid-dependent youth. 
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Slide 34:  Views on Medication-Assisted Treatment 
 
Preparation prior to the training is needed for this activity.  
Prepare one sign that says “1   Strongly Disagree” and 
one that says “10   Strongly Agree.”  Prior to the training, 
identify an area where participants can line up, shoulder 
to shoulder across the room.  Post one sign on either side 
of this area.  This will clearly demark the scaling ruler 
area for this activity. 
 
Before we examine the findings of the CTN study, let’s talk 
about your views on the use of medications in the treatment of 
substance use disorders – also known as pharmacotherapy.  
Medications are playing an increasingly important role as 
adjuncts to psychosocial strategies of addiction treatment. 
Although problems associated with the use of alcohol and 
other drugs often appear in adolescence, most studies of 
pharmacotherapy for drugs of abuse have been conducted 
with adults.  Because young adults may react differently than 
adults to both the therapeutic and potentially harmful effects of 
medications, the applicability of existing data to young adults 
who abuse alcohol and other drugs often remains unclear. 
 
ACTIVITY – 20 to 30 minutes 
 
The purpose of this activity is to increase awareness about 
counselor attitudes regarding the use of medication for 
substance use disorders in young adults, and foster open-
mindedness to new pharmacotherapies. The activity consists 
of a “virtual” scaling ruler that spans the training room or other 
convenient location.  The side of the virtual ruler that has a “1” 
means that the participants “Strongly Disagree” with the 
statements that are being read.  The side of the virtual ruler 
that is marked with a “10” means that participants “Strongly 
Agree” with the statements that are being read. 
 
(Instruction continued below) 
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 Slide 34: Views on Medication-Assisted Treatment 
(continued) 
 
Read three of the statements below related to counselor 
willingness to try new therapies in general, reliance upon 
research or colleagues to guide new treatment practices, 
and attitudes about medication-assisted treatment.  
Instruct participants to stand on the virtual scaling ruler 
depending upon how they feel about the statement – from 
Strongly Disagree to Strongly Agree.  For each statement, 
facilitate a discussion by asking participants to share 
their reasons or beliefs that impact where they stand on 
the scaling ruler.  In a motivational interviewing style, you 
can also selectively ask participants what it would take to 
move their beliefs, values or attitudes in either direction. 
 
Statements for the Activity: 
 
1. I like to use new types of therapy or interventions to 
help my clients. 
2. I stay abreast of clinical research to help in guiding 
treatment interventions for my clients. 
3. Medications should only be used with adolescents as a 
treatment of last resort. 
4. The use of medications for adolescents and young 
adults can play a key role in treating their substance 
use disorders. 
5. The goal of pharmacotherapy with adolescents should 
be withdrawing them from the medication as quickly as 
possible. 
 
Sample Script:  Sally, when asked how you feel about the 
use of medications in the treatment of substance abuse in 
young adults, you indicate you are a 4 on the scale.  Why 
are you a 4? Why are you a 4 instead of a 2?   What would 
it take for you to move to an 8 on the scale? 
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Slide 35:  The Big Question (Video Clip) 
 
While many providers are willing to consider using 
medications such as buprenorphine with older, long-term 
opioid users, they do not want these medications used with 
their young clients. 
 
Here is how one provider felt about medication assisted 
treatment with the young clients that he served. 
 
Move mouse over black box. It will turn into an image of a 
hand. Click on the black box and the movie will play. 
 
Discussion: Facilitate a discussion with participants 
gathering reactions to the video clip. 
 
Slide 35 
 
 
 
 
 
 
 
 
 
 
 
Slide 36:  Areas of Concern 
 
Many doctors have been reluctant to treat young adults with 
pharmacotherapy for addictive disorders because research on 
the safety and efficacy of these drugs in this population was 
lacking, therefore, there was relatively little guidance on: 
 
 appropriate dosing;  
 duration of medication treatment; and 
 medication side effects, interactions with other drugs, 
and other safety issues. 
 
Additionally, NIDA research shows that adolescents and 
young adult opioid users present for treatment with multiple 
co-occurring issues that complicate treatment and must be 
addressed for treatment to be effective. 
 
References: 
 
Subramaniam, G. A., & Stitzer, M. A. (2009). Clinical characteristics of 
treatment-seeking prescription opioid vs. heroin-using adolescents with 
opioid use disorders. Drug and Alcohol Dependence, 101(1-2), 13-19. 
 
Subramaniam, G. A., Stitzer, M. L., Woody, G., Fishman, M. J., & Kolodner, 
K. (2009). Clinical characteristics of treatment-seeking adolescents with 
opioid versus cannabis/alcohol use disorders. Drug and Alcohol 
Dependence, 99, (1-3), 141-149. 
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Slide 37:  Areas of Potential Concern about Using 
Buprenorphine with this Population 
 
Other issues that compound the reluctance to use 
buprenorphine with young adults are: 
 general philosophical concerns among clinicians against 
medication-assisted treatment for substance abuse;  
 denial of severity of addiction by family; 
 poor medication compliance among youth; 
 hampered ability to determine efficacy of medications 
due to denial, and poor compliance with both 
psychosocial treatment and the taking of medications; 
and 
 the effect on the young adult brain of exposure of illicit or 
prescribed opioids (including partial agonists) is 
unknown. 
 
Slide 37 
 
Slide 38:  The Medication Buprenorphine/Naloxone 
(Transition Slide) 
 
It is clear from the previously presented statistics that opioid 
use is a significant problem among this population.   
 
In order to understand the results of the study using this 
medication with young adults, it is important that we 
understand how the medication (buprenorphine/naloxone) 
works.  In the next section, we will look at the mechanism of 
action of this medication and issues pertaining to its efficacy 
and safety. 
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Slide 39:  Partial vs. Full Opioid Agonist and Antagonist 
 
This slide graphically depicts the different types of opioids 
(whether they are prescribed medications such as Vicodin or 
methadone, or an illicit substance like heroin). 
Move forward to reveal first line (full agonist) 
Full agonists (e.g., heroin, opium, Vicodin, methadone, etc.), 
fully activate the receptors so that the more you use, the 
more effect you experience.  If someone continues to use, 
they will eventually experience overdose and, possibly, 
death.   
The following metaphor may be helpful in explaining the 
differences between the types of opioids: 
Opioid agonists work like having the right key to a door.  You 
put the key in the lock, the lock turns and the door opens 
completely.  
Move forward to reveal the next line (antagonists) 
Opioid antagonists (e.g., naltrexone, naloxone) fill the 
receptors and block the action of other opioids. If the person 
has used an opioid agonist, the antagonist will replace it on 
the receptor and the person will experience withdrawal.  If 
the person is stable on an antagonist, and uses another 
opioid, the antagonist will block the effects, preventing the 
user from experiencing the high. 
The door metaphor continued: 
Opioid antagonists work like having the wrong key to a door.  
You put the key in the lock; the door remains locked and will 
not open.  Additionally, since the key is in the lock, no other 
key can be put in the lock (even if it is the right key for that 
door) until the wrong key is removed. 
Move forward to reveal the last line (partial agonists) 
Opioid partial agonists (e.g., buprenorphine) are in the 
middle.  At lower doses, they work just like agonists, filling 
the receptor and preventing withdrawal symptoms.  
However, as the dose increases, a ceiling effect occurs so 
that if more is used, no more effect is achieved.  This ceiling 
effect applies both to opioid euphoria (they don’t feel high), 
and to the respiratory suppression (making overdose less 
likely). 
The door metaphor continued: 
Opioid partial agonists work like having the right key to a 
door, but the chain is on the door.  The key goes in and 
opens the door, but it will only open so far.   
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Slide 40:  Buprenorphine 
 
As mentioned in the previous slide, buprenorphine is a partial 
agonist.  It has been shown to be safe and effective for the 
treatment of opioid dependence both as a maintenance agent 
and for use during withdrawal from opioids. 
Buprenorphine binds to the receptors very strongly and comes 
off very slowly.  This makes it a very long lasting medication 
that continues to be effective even if a dose is missed. 
Another advantage is that the FDA approval for the medication 
is for opioid dependent individuals age 16 and older.  It is 
possible to use the medication with younger adolescents if 
determined medically appropriate (benefits outweigh the 
risks).  However, this would be off-label use and the patients 
must be monitored very closely due to the lack of clinical 
research data. 
 
Slide 40 
 
Slide 41:  Development of Tablet Formulations of 
Buprenorphine  
 
Buprenorphine was developed by a pharmaceutical company 
called Reckitt Benckiser.  They have/had exclusive marketing 
rights until Fall 2009, and distribute the medication as  
 
Subutex® = a sublingual tablet containing buprenorphine 
hydrochloride only  
  
Suboxone® = a sublingual tablet containing both 
buprenorphine hydrochloride and naloxone hydrochloride in a 
4:1 ratio  
  
Reckitt Benckiser’s exclusive rights expire/expired in the fall of 
2009, so generic versions of the medication may become 
available in the future.   
 
Buprenorphine/naloxone is the focus of U.S. marketing 
efforts, even though both formulations are available in the U.S.  
 
These medications have a tremendous amount of research 
behind them to show that they are both safe and effective in 
the treatment of opioid addiction. 
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Slide 42:  Buprenorphine: A Science-Based Treatment 
 
In the development of the medication, the effectiveness of 
buprenorphine has been compared to that of other currently 
available medications.  These studies have shown that 
buprenorphine treatment: 
- is more effective than placebo; and 
- has similar effectiveness to moderate doses of methadone 
and LAAM. 
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Strain, E. C., Stitzer, M. L., Liebson, I. A., & Bigelow, G. E. (1994). 
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Slide 43:  Buprenorphine Research Outcomes 
 
Clinical trials have established the effectiveness of 
buprenorphine for the treatment of opioid addiction. The 
clinical studies have shown the following about buprenorphine:  
  
Bullet #1:  Patients on buprenorphine did as well as patients 
on a moderate dose of methadone (e.g., 60mg).  
 
Bullet #2:  Patients on buprenorphine did as well as patients 
on a moderate dose of LAAM (70mg/70mg/85mg on a 
Monday/Wednesday/Friday schedule).   
 
Bullet #3: Patients found that taking buprenorphine was a 
pleasant experience, which encouraged them to be compliant. 
 
Bullet #4:  When compared to placebo-plus-counseling, 3/4 of 
the patients receiving buprenorphine and counseling were still 
in treatment after one year.  None of the placebo patients 
were retained.  
 
References: Bullet #1 
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713–720. 
 
Strain, E. C., Stitzer, M. L., Liebson, I. A., & Bigelow, G. E. (1994). 
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Slide 44:  Why did they make two formulations? 
 
As previously stated, the focus of marketing in the U.S. and 
the formulation used in the CTN studies is the 
buprenorphine/naloxone combination. Understanding why this 
combination was made is critical. 
 
Slide 44 
 
Slide 45: Advantages of Buprenorphine/Naloxone  
 
The buprenorphine/naloxone formulation has some 
advantages compared with the buprenorphine only 
formulation:  
• It discourages injection of the product because, when 
injected, the naloxone will lead to withdrawal, whereas 
when taken sublingually as prescribed, it will not have 
that effect.  
• Because of the above point, the combination tablet lowers 
the likelihood that the medication will be diverted.  
  
Slide 45 
 
Slide 46:  Use of Buprenorphine: Studies on Cost-
Effectiveness 
  
There has been much discussion regarding the costs 
associated with the use of buprenorphine for the treatment of 
opioid dependence. When considering the costs of providing 
treatment you must also include costs associated with clinic 
visits, staff time, and general operating and facility 
expenditures.  
 
Recently, research conducted on adult populations has 
demonstrated the utilization of buprenorphine is cost effective 
across several indicators. 
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Slide 47:  Use of Buprenorphine: Studies on Cost-
Effectiveness 
  
Doran and colleagues (2003) conducted a clinical trial 
designed to assess the safety, efficacy and cost-effectiveness 
of buprenorphine versus methadone in the management of 
opioid dependence.  The trial utilized a flexible dosing regime 
that was tailored to the clinical need of the patients, with high 
maximum doses, using the marketed tablet formulation, under 
double-blind conditions. A total of 405 subjects were 
randomized to a treatment at one of three specialist outpatient 
drug treatment centers in Adelaide and Sydney, Australia. The 
perspective of the cost-effectiveness analysis was that of the 
service provider and included costs relevant to the provision of 
treatment. The primary outcome measure used in the 
economic analysis was change in heroin-free days from 
baseline to the sixth month of treatment. 
 
Key findings included: 
 Both buprenorphine and methadone demonstrated 
increases in heroin-free days; and  
 There was no statistical significance between the cost-
effectiveness for buprenorphine and methadone. 
 
Reference: 
 
Doran, C. M., Shanahan, M., Mattick, R. P., Bell, J., White, J., & Ali, R. 
(2003). Buprenorphine versus methadone maintenance: A cost 
effectiveness analysis.  Drug and Alcohol Dependence, 71(3): 295 – 302. 
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Slide 48:  Use of Buprenorphine: Studies on Cost-
Effectiveness, cont’ 
  
Another study conducted by Kaur and McQueen (2008) found 
that the treatment with buprenorphine/naloxone was 
associated with a reduction in opioid utilization and cost in the 
first year of follow-up. 
 
Doran (2008) conducted a systematic review of the literature 
and found a number of studies supporting buprenorphine as a 
cost-effective approach to opioid treatment. 
 
References: 
 
Doran, C. M. (2008). Economic evaluation of interventions to treat opiate 
dependence: a review of the evidence. Pharmocoeconomics, 26(5), 371-
393. 
 
Kaur, A. D., McQueen, A. & Jan, S. (2008). Opioid drug utilization and cost 
outcomes associated with the use of buprenorphine-naloxone in patients 
with a history of prescription opioid use. Journal of Managed Care 
Pharmacy, 14(2), 186-194. 
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Slide 49:  Use of Buprenorphine: Studies on Cost-
Effectiveness, cont’ 
 
This study was the first to examine the cost effectiveness of 
buprenorphine as maintenance treatment for heroin 
dependence in a primary care setting. The study was a 
randomized, open-label, 12-month trial of 139 heroin-
dependent patients in a community setting receiving 
individualized treatment regimens of buprenorphine or 
methadone.  The study took a broad societal perspective and 
included health, crime and personal costs.  The main 
outcomes were incremental cost per additional day free of 
heroin use and per the quality adjusted life years (QALY). 
 
The researchers found that buprenorphine demonstrated 
lower crime costs and higher quality adjusted life years. 
 
Reference: 
 
Harris, A. H., Gospodarevskaya, E., & Ritter, A. J. (2005). A randomised trial 
of the cost effectiveness of buprenorphine as an alternative to methadone 
maintenance treatment for heroin dependence in a primary care setting. 
Pharmocoeconomics, 23(1), 77-91.  
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Slide 50:  What is the Ratio of Buprenorphine to Naloxone 
in the Combination Tablet? 
 
The combination includes buprenorphine and naloxone in a 
ratio of 4:1.   
 
This ratio was found to maintain the clinical effects when taken 
sublingually as intended, BUT cause sufficient discomfort if 
injected by a physically dependent patient (to discourage them 
from doing so). 
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Slide 51:  Why Combining Buprenorphine and Naloxone 
Sublingually Works 
 
Digestive juices would kill buprenorphine’s effects if you were 
to swallow it. By administering it sublingually, the medication 
dissolves under the tongue and is absorbed directly into the 
blood stream. Buprenorphine and naloxone have very different 
absorption rates when taken this way.  
 
When taken under the tongue, the person receives 
approximately 40-60% of the buprenorphine available, but 
only 10% of the naloxone.  
  
However, when you look at the relative potency comparing 
sublingual administration to injection, buprenorphine is 
approximately twice as strong when injected as when taken 
sublingually. Naloxone, on the other hand, is 15 times more 
effective by injection.  
  
This means that when taken by injection, the naloxone is the 
stronger medication and the antagonist effects dominate.  
 
Reference: 
 
Chiang, C.N, & Hawks, R.L., (2003).  Pharmacokinetics of the combination 
tablet of buprenorphine and naloxone.  Drug and Alcohol Dependence, 70, 
S39-S47. 
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Slide 52:  Buprenorphine/Naloxone: What You Need to 
Know 
 
 The effect of the combination tablet is virtually identical 
to the buprenorphine-only product when taken 
sublingually. 
 Both formulations demonstrate the ceiling effect at 
higher doses. 
 Both formulations prevent the intoxicating effects if 
someone decides to also use another opioid. 
 They are long-acting because of the high receptor 
affinity; meaning they bind strongly to the receptor site. 
 
Additional Information for the Trainer(s): 
 
Safety  
 
Because of its ceiling effect and poor bioavailability, 
buprenorphine is safer in overdose than opioid full agonists. 
The maximal effects of buprenorphine appear to occur in the 
16–32 mg dose range for sublingual tablets. Higher doses 
are unlikely to produce greater effects.  
Respiratory depression from buprenorphine (or 
buprenorphine/ naloxone) overdose is less likely than from 
other opioids. There is no evidence of organ damage with 
chronic use of buprenorphine, but increases in liver 
enzymes are sometimes seen. There is no evidence of 
significant disruption of cognitive or psychomotor 
performance with buprenorphine maintenance dosing.  
 
Side Effects  
 
Side effects of buprenorphine are similar to those of other 
opioids and include nausea, vomiting, and constipation. 
Buprenorphine and buprenorphine/naloxone can precipitate 
the opioid withdrawal syndrome. Additionally, the withdrawal 
syndrome can be precipitated in individuals maintained on 
buprenorphine. 
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Slide 53:  NIDA-Supported Research Study: 
Buprenorphine for Adolescents with Opioid Use Disorder 
 
Marsch and colleagues (2005) conducted a randomized 
controlled trial where participants were assigned to a 28-day, 
outpatient, medication-assisted withdrawal treatment with 
either buprenorphine or Clonidine. Both medications were 
provided along with thrice weekly behavioral counseling and 
incentives contingent on opiate abstinence. 
 
Study findings indicated that a significantly greater percentage 
of adolescents who received buprenorphine were retained in 
treatment (72%) relative to those who received clonidine 
(39%). For those in the buprenorphine group, a significantly 
higher percentage of scheduled urine test results were opiate 
negative (64% vs 32%).  
 
Overall, it was found that combining buprenorphine with 
behavioral interventions was significantly more efficacious in 
the treatment of opioid-dependent adolescents relative to 
combining clonidine and behavioral interventions.  
 
Reference: 
 
Marsch, L. A., Bickel, W. K., Badger, G. J., Stothart, M. E., Quesnel, K. J., 
Stanger, C., et al. (2005). Comparison of pharmacological treatments for 
opioid-dependent adolescents: a randomized controlled trial. Archives of 
General Psychiatry, 62(10), 1157-1164. 
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Slide 54:  Extended vs. Short-term Buprenorphine-
Naloxone for Treatment of Opioid-Addicted Young Adults:  
The CTN Clinical Trial 
 
The next series of slides will present information on the NIDA 
CTN clinical trial conducted by Dr. George Woody comparing 
a 14-day vs. 12-week taper using buprenorphine/naloxone 
with young adults. 
 
Reference: 
 
Woody, G. E., Poole, S. A. Subramaniam, G., Dugosh, K., Bogenschutz, M., 
Abbott, P., et al. (2008). Extended vs short-term buprenorphine-naloxone for 
treatment of opioid-addicted youth: a randomized trial. Journal of the 
American Medical Association, 300(17), 2003-2011. 
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Slide 55:  The Context of the Study 
 
Adult clinical trials using buprenorphine to help people 
withdraw from opioids have shown it to be effective.  However, 
the number of young adults in these studies is so small that 
generalizing the findings to this population is not possible. 
 
Additionally, current standard practice is to withdraw young 
adults quickly using clonidine, buprenorphine or methadone, 
followed by weeks or months of counseling. 
 
The CTN Trial compares two strategies for tapering young 
adults off of opioids. One group received a short-term (14-day) 
taper (comparable to standard practice) and the other group 
received longer treatment, which included stabilization and a 
taper over a 12-week period. 
 
The goal of the study was to determine the relative efficacy of 
doing longer versus shorter medically-assisted withdrawal 
(detoxification) using buprenorphine. 
 
Slide 55 
 
Slide 56:  Study Locations 
 
Move forward and site locations will appear one at a time. 
This slide shows the sites that participated in the clinical 
trial.  There were three sites in the eastern U.S. and two in 
the west. 
 
Additional Information for the Trainer(s): 
The CTN works to ensure diversity among participating sites 
(geography, client demographics, etc.) to maximize 
generalizability.  CTN Nodes self-select community 
treatment programs for participation in a protocol based on 
interest in the protocol and the ability to recruit appropriate 
participants into the study (i.e., clients served by the agency 
are representative of the target population for the study). 
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Slide 57:  Inclusion and Exclusion Criteria 
 
Move forward to reveal the five inclusion and nine 
exclusion criteria one at a time.  After the last exclusion 
criterion, the bubble with the words “Study Participants” 
will appear automatically after a few seconds. 
 
Inclusion Criteria (notes for each bullet are below): 
 While the lower age limit was 14, very few participants 
under the age of 18 were enrolled, limiting generalizabilty 
of results to those 18-21. 
 All participants were opioid dependent. 
 All participants were able to understand the requirements 
of the study and provide informed consent. 
 If participant was under 18 years of age, parent/guardian 
provided consent and the minor provided their assent to 
participate. 
 All participants (and parents where appropriate) were 
required to complete and pass a study quiz to document 
their understanding of the requirements of participation. 
 
Exclusion Criteria (notes for each bullet are below): 
 Clients were excluded from participation if they were 
determined to have a medical or psychiatric condition that 
would make their participation unsafe. 
 They were also excluded if they had a psychiatric 
condition of sufficient severity to warrant medical 
treatment, except for SSRI medication. 
 Clients who were unlikely to finish the protocol because 
they were going to be incarcerated or were likely to leave 
the area were excluded. 
 
Because of the risks of combining buprenorphine with 
CNS depressants, several criteria addressed this issue: 
Participants were excluded if they: 
 met DSM-IV criteria for abuse of alcohol or sedatives; 
 had a sedative overdose in the previous 6 months; 
 were determined to have used benzodiazepines (benzos) 
more than 15 of the past 28 days; or, 
 were unable to provide a urinalysis (UA) that was 
negative for both benzos and methadone during the 
screening process. 
 
Because buprenorphine is not approved for use in 
pregnancy, female clients were excluded if: 
 they were pregnant or breastfeeding; or, 
 were unable or unwilling to commit to using an approved 
method of birth control. 
 
Participants who met all inclusion and no exclusion were 
eligible for randomization into the trial. 
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Slide 58:  Counseling 
 
All participants in the trial were asked to participate in a 
minimum of one individual and one group counseling session 
per week, but more frequent sessions could be scheduled. 
 
The counseling provided at each site included methods shown 
to be successful and have been published in NIDA treatment 
manuals, including Cognitive Behavioral Therapy (CBT), 
referrals to additional treatment, and referrals to age-
appropriate self-help groups. 
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Slide 59:  Study Design 
 
Move forward to reveal first row of chart (Screening) 
A total of 236 individuals completed the consent process 
and entered screening.   
 
Move forward to reveal next row of chart (Randomization) 
Of these 236 individuals, 154 met all of the inclusion criteria, 
and none of the exclusion, and were randomized into the 
study. 
 
Move forward to reveal next row of chart (Detox/12-Week) 
The randomization resulted in 80 participants in the short-
term detoxification group and 74 people in the 12-week 
group. 
 
Move forward to reveal next row of chart (Withdrew).  
After the row appears, a box will automatically fly in from 
the bottom showing the reasons why participants 
withdrew. 
More people withdrew from the detoxification group than the 
12 week group.  The reasons for withdrawal and the 
numbers in each group are depicted in the black box.  
Reasons included: not taking the medication as prescribed, 
leaving the study to enroll in another treatment program, 
voluntarily withdrawing, and being incarcerated. One person 
in the 12-week group died.  Upon investigation, he was 
found to have dropped out of the study very early and died 
from an overdose of methadone. 
 
Move forward to reveal next row of chart (Completed Tx) 
Of the randomized people in each group, 20% (16/80) 
completed in the detoxification group and 70% (54/74) 
completed in the 12-week group. 
 
Move forward to reveal final row of chart (Included in 
Primary Analysis) 
Once enrolled, all participants (completed treatment or 
withdrew) were included in the final analysis, except for 2 
individuals in the detoxification group who were randomized, 
but left the study prior to receiving their first dose of study 
medication. 
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Slide 60:  Medication Dosages 
 
The medication for all participants was the 
buprenorphine/naloxone combination tablet.  Medication was 
administered at the study site five or seven days per week.  
Some of the sites were closed on the weekends, so 
medications were administered on-site five days per week and 
take home doses were provided to participants for days that 
the program was closed. 
 
All doses administered on-site were directly observed by study 
personnel. 
 
Slide 60 
 
Slide 61:  Medication Dosages 
 
Medication dosages were identical for all participants on the 
first three study days. 
 
On Day 1, all participants were administered a 2-mg dose and 
observed for 1.5 to 2 hours.  A second dose of 2 to 6 mg could 
be administered as determined by the study physician. 
 
On Day 2, participants received the total dose received on 
Day 1 and then were observed for 1.5 to 2 hours.  Again, an 
additional dose of 2 to 6 mg could be administered, as 
needed. 
 
On Day 3, participants received the total dose received on 
Day 2 and they were observed for 1.5 to 2 hours.  Again, an 
additional dose of 2 to 6 mg could be administered, as 
needed. 
 
Slide 61 
 
Slide 62:  Medication Dosages 
 
Beginning on Day 4, medication dosages were determined 
according to study group assignment.  
 
In the Detoxification Group, the maximum allowable dose was 
14 mg; the taper was begun immediately and scheduled so 
that it was completed by Day 14. 
 
In the 12-week Group, the maximum allowable dose was 24 
mg.  Participants were stabilized on the clinically appropriate 
dose for the first 8 weeks.  Beginning at Week 9, the taper 
was begun and scheduled so that it was completed by the end 
of Week 12. 
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Slide 63:  Medication Dosages 
 
According to the study protocol, medication was stopped if 
three consecutive doses were missed.  What happened then 
depended on group assignment: 
 For the Detoxification Group, the medication was not 
restarted once it was stopped. 
 For the 12-week Group, the medication was restarted if 
the participant returned for dosing within 7 days.  It was 
restarted at half of the last dose administered, and the 
participant was observed for 1.5 to 2 hours.  If the 
medication was well tolerated, the remaining portion of 
the dose was administered. 
 
Regardless of which group they were in, all participants were 
encouraged to continue in counseling if the medication was 
stopped. 
 
Slide 63 
 
Slide 64:  Study Design 
 
This slide serves as a reminder of the participants included in 
the final analysis. 
 
Call attention to the bottom boxes and remind people that 
all participants who were enrolled in the trial were 
included in the analysis, even those who dropped out 
early.  The only exception to this is the two participants 
who were randomized, but never received treatment.  
These two were excluded from the analysis, resulting in 
78 in the Detoxification Group and 74 in the 12-week 
Group. 
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Slide 65:  Study Demographics 
 
Demographic information was similar across the two groups.   
 
Move forward to reveal first column (% Male) 
Participants were mostly male. 
 
Move forward to reveal next column (% < 18) 
Very few were under the age of 18 years.  These 
percentages indicate that only 14 Detoxification and 12 12-
week participants were in this age group.  This limits 
generalizability. 
 
Move forward to reveal last column (% Ethnicity) 
Participants were roughly ¾ Caucasian and ¼ Hispanic.  
While this reflects the current demographics of young users, 
the low number of African-Americans limits generalizabilty of 
findings to this population. 
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Slide 66:  The Results: Opioid Positive Urine Tests 
 
Move forward to reveal data for Weeks 4 and 8. 
Results were that Detoxification patients were more likely to 
provide opiate-positive urine test results at Week 4 and 
Week 8… 
 
Move forward to reveal data for Week 12 
…but not week 12.  This is significant as it is between 
Weeks 8 and 12 that the people in the 12-week Group are 
tapered off of the buprenorphine/naloxone. 
 
Move forward to reveal data for months 6-12 
At the 6-, 9-, and 12-month follow-up points, participants in 
the Detoxification Group provided higher proportions of 
positive urine results than patients in the 12-week 
buprenorphine-naloxone Group.  Further research is needed 
to determine if this effect is associated with the treatment 
received in this study. 
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Slide 67:  What About the Other Indicators? 
 
This table shows the results of comparisons on a variety of 
additional indicators of treatment success.  The plus signs 
indicate the variables that were statistically different.   
 
We will look at each variable that show a difference between 
groups. 
 
First, retention in the trial.  The plus sign under 12-week 
indicates that the participants in the 12-week group were 
retained in the trial longer than the participants in the 
Detoxification group. 
 
Move forward to the first graph (Retention in Trial) 
As this graph indicates, at each time point during the active 
trial, the percentage of 12-week participants that were active 
in trial was higher than in the Detoxification group. 
 
Move forward to the next graph (# Counseling Sessions) 
While not statistically significant, there was a trend indicating 
a possible difference in the number of counseling sessions 
attended, with the 12-week Group attending more sessions 
on average than the Detoxification Group. 
 
Move forward to the next graph (Marijuana Use During 
Trial) 
The investigators also looked at other drug use during the 
trial and during the follow-up period.  Marijuana use was 
higher in the Detoxification group at all three timepoints 
during the trial.  However, it is of note that the groups did not 
differ in marijuana use after the trial. 
 
Move forward to the next graph (Cocaine Use During and 
After Trial) 
In the adult population, cocaine use is frequently seen 
among opioid users.  In this trial, cocaine use was higher 
among the Detoxification Group both during the trial and 
during the follow-up period. 
 
Move forward to the final graph (IDU During Trial) 
Injection drug use was found to be higher in the 
Detoxification Group during the trial period.  However, during 
the follow-up period, the groups again did not differ in their 
use of needles.  
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Slide 68:  Baseline Hepatitis C Rates 
 
One disease that frequently occurs with substance use is 
Hepatitis C, especially for those drugs that are used by 
injection, but Hepatitis C can also be spread in other ways as 
well (e.g., sharing straws while using intranasally).   
 
Because of the high co-morbidity, investigators examined both 
baseline rates of Hepatitis C in the study sample and during 
their participation in the study. 
 
It was shown that nearly one in five participants were Hepatitis 
C positive upon entering the trial.  This clearly indicates the 
high prevalence in the population from which the sample was 
drawn, and therefore the risk of exposure and infection. 
 
It is of additional note that 4 of the 83 participants who were 
Hepatitis C negative at baseline, converted to positive during 
the fairly short duration of this trial.  This again, clearly 
indicates the risk of infection with this disease. 
 
One of the benefits of appropriate treatment with medications 
such as buprenorphine, is that it eliminates (or at least 
reduces) the risky behavior associated with illicit substance 
use, thereby reducing comorbid factors, such as Hepatitis C.  
This is another indicator that use of these medications over 
longer (rather than shorter) periods of time may be warranted 
as part of standard care (Thiede, Hagan & Murril, 2000). 
 
Reference: 
 
Thiede, H., Hagan, H., & Murrill, C.S. (2000). Methadone treatment and HIV 
and hepatitis band C risk reduction among injectors in the Seattle area. 
Journal of Urban Health, 77, 331-45. 
 
Slide 68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Slide 69:  Implications of the Study  
 
The study by Woody et al. (2008) provided implications for 
effective treatment of adolescents and young adults through 
longer-term opioid antagonist treatment. This was 
demonstrated by the fact that opioid-depended adolescents 
and young adults showed significantly greater abstinence and 
treatment retention while receiving buprenorphine/naloxone. 
 
Reference: 
 
Woody, G. E., Poole, S. A. Subramaniam, G., Dugosh, K., Bogenschutz, M., 
Abbott, P., et al. (2008). Extended vs short-term buprenorphine-naloxone for 
treatment of opioid-addicted youth: a randomized trial. Journal of the 
American Medical Association, 300(17), 2003-2011. 
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Slide 70:  High Prevalence among Young Adults 
 
Though heroin use has been deemed stable, there continues 
to be a high prevalence of opioid use among young adults and 
adolescents. In fact, much concern has been voiced with 
regards to non-medical use of prescription opioids among the 
current adolescent generation.  
 
Other concerns regarding adolescent use of opioids include 
the willingness of many adolescents to experiment with drugs 
while not being knowledgeable of neurobiological changes 
that accompany opioid abuse and dependence (Fiellin, 2008).  
 
Although we know that long-term outcomes among addicted 
adults are poor, there are many unknowns regarding long-
term prognosis among addicted young adults. Lack of 
knowledge, coupled with the fact that most adolescents’ brains 
have not yet reached maturity, leads to a dangerous, vicious 
cycle of experimentation, impairment, and dependence. This 
has also led to high rates of school drop out, legal problems, 
psychiatric problems, and high risk behaviors. 
 
Reference: 
 
Fiellin, D. A. (2008).  Treatment of adolescent opioid dependence: No quick 
fix. Journal of the American Medical Association, 300(17), 2057-2059. 
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Slide 71:  High Prevalence among Young Adults 
 
Review the bullets on the slide and ask participants what 
they think are some of the reasons for low rates of 
admission for young adults into treatment programs for 
opioid addiction. 
  
If it is not mentioned, bring up the fact that one of the 
challenges associated with the use of prescribed 
medications is the stigma associated with the use of 
medication as an aid to one’s recovery, not just among 
the general population but also those in the addiction 
counseling profession, even though research seems to 
indicate more benefits of prescribed medications than 
risks.   
 
Other challenges to discuss: 
 Common long-term treatment for opioid addiction 
(methadone maintenance) is not readily available to 
young adults and adolescents and is not an option for 
patients under 16 years of age.  
 A requirement by many programs and/or jurisdictions is 
that those between 16 and 18 can only be admitted for 
treatment if they have had two failed behavioral treatment 
episodes along with a legal guardian’s consent. 
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Slide 72: One Provider’s Perspective on How to Make 
Buprenorphine as Effective as Possible (Video Clip) 
 
After gaining experience with buprenorphine, Shannon Garret 
understood how effective this treatment can be. However, he 
emphasized the importance of a multidisciplinary approach to 
treatment. 
 
Move mouse over black box. It will turn into an image of a 
hand. Click on the black box and the movie will play. 
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Slide 73: So What Did We Learn? 
 
In summary, let’s look at the lessons that were learned from 
comparing a 14-day versus 12-week taper using 
buprenorphine/naloxone with young adults. 
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Slide 74:  Lessons Learned 
 
The information in the next three slides reviews the findings of 
this CTN research trial indicating that longer-term treatment 
with buprenorphine/naloxone may be more effective for young 
patients than short-term term detoxification.  
 
Review each bullet and facilitate discussion by asking 
participants what they think are some of the reasons why 
longer term treatment works better than short-term 
detoxification for this age group. 
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Slide 75:  Lessons Learned 
 
Continue reviewing bullets and allowing for discussion 
about the meaning of each one to the training 
participants. 
 
In addition, re-emphasize the following findings for 
participants in the 12-week buprenorphine/naloxone 
Group when compared with the short-term Detoxification 
Group: 
 Less use of opioids, cocaine, and marijuana 
 Better treatment retention 
 Less injection of drugs 
 Less need for additional treatment 
 
References: 
 
Fiellin, D. A. (2008).  Treatment of adolescent opioid dependence: No quick 
fix. Journal of the American Medical Association, 300(17), 2057-2059. 
 
Woody, G. E., Poole, S. A. Subramaniam, G., Dugosh, K., Bogenschutz, M., 
Abbott, P., et al. (2008). Extended vs short-term buprenorphine-naloxone for 
treatment of opioid-addicted youth: a randomized trial. Journal of the 
American Medical Association, 300(17), 2003-2011. 
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Slide 76:  Lessons Learned 
 
Continue reviewing bullets and allowing for discussion 
about the meaning of each one to the training 
participants. 
 
It is important to continue providing supportive counseling 
during the taper period.  
 
Ask participants to give examples in their practice of how 
they provide support to their patients during such a taper 
process. 
 
Also, discuss the efficacy of using naltrexone following 
the buprenorphine taper. Include the following in the 
discussion: 
 Naltrexone is an opioid receptor antagonist; 
 It can only be used after discontinuation of buprenorphine; 
 It blocks the ability of endogenous opioids to stimulate the 
receptor; and 
 It can assist the patient in remaining drug free as part of a 
long-term recovery counseling program. 
 
References: 
 
Fiellin, D. A. (2008).  Treatment of adolescent opioid dependence: No quick 
fix. Journal of the American Medical Association, 300(17), 2057-2059. 
 
Woody, G. E., Poole, S. A. Subramaniam, G., Dugosh, K., Bogenschutz, M., 
Abbott, P., et al. (2008). Extended vs short-term buprenorphine-naloxone for 
treatment of opioid-addicted youth: a randomized trial. Journal of the 
American Medical Association, 300(17), 2003-2011. 
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Slide 77:  Limitations of the Study 
 
Although a need for extended medication-assisted treatment 
for young adults seems to exist (Subramaniam, et al., 2009), 
there is a call for further research to substantiate the efficacy 
of extended buprenorphine/naloxone treatment for this age 
group. The following limitations were discussed in the study by 
Woody, et al. (2008): 
 The number of participants under the age of 18 was 
rather small; 
 There was a total absence of African-American 
participants in the study; 
 The study lacked a significant number of blind evaluators; 
 There was missing follow-up data, making estimates on 
those achieving full recovery difficult; and 
 The number of participants was too small to capture any 
adverse effects of the medication.  
 
References: 
 
Subramaniam, G. A., Stitzer, M. L., Woody, G., Fishman, M. J., & Kolodner, 
K. (2009). Clinical characteristics of treatment-seeking adolescents with 
opioid versus cannabis/alcohol use disorders. Drug and Alcohol 
Dependence, 99, (1-3), 141-149. 
 
Woody, G. E., Poole, S. A. Subramaniam, G., Dugosh, K., Bogenschutz, M., 
Abbott, P., et al. (2008). Extended vs short-term buprenorphine-naloxone for 
treatment of opioid-addicted youth: a randomized trial. Journal of the 
American Medical Association, 300(17), 2003-2011. 
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Slide 78:  Additional Limitations of the Study 
 
Additional limitations of the study, as discussed by Fiellin 
(2008) included: 
 Naltrexone was not offered to patients following 
buprenorphine/naloxone taper, thus potentially adversely 
effective abstinence; 
 The medication was dispensed from offices or clinics and 
not provided by prescription, which may have confounded 
the study;  
 Counseling was only offered twice each week, which may 
have increased the drop out rate; and 
 The trial was too small to form conclusions relating to the 
safety of buprenorphine/naloxone for adolescents. 
 
Reference: 
 
Fiellin, D. A. (2008).  Treatment of adolescent opioid dependence: No quick 
fix. Journal of the American Medical Association, 300(17), 2057-2059. 
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Slide 79:  Further Research Needed 
 
Address the bullets on the next two slides with a 
discussion of further research.  
 
There is a need for developing prevention strategies for opioid 
use among young adults; further research on initial opioid use 
for this age group will be helpful in this effort. 
 
More research is also needed on the efficacy of offering other 
medications, either as alternatives to buprenorphine, or as a 
narcotic antagonist following buprenorphine taper. 
 
Research should also be conducted to compare 
buprenorphine treatment to non-medical approaches. 
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Slide 80:  Further Research Needed 
 
Continue the discussion on further research by reviewing 
the bullets on this slide.  Ask participants for their input 
on further research needs. Include in the discussion the 
following: 
 Little is known about using medication-assisted treatment 
for longer terms with young adults. More research is 
needed to broaden our understanding of the safety and 
effectiveness and the optimal length for such treatment. 
 While medication-assisted treatment is known to reduce 
risk behaviors for HIV, HCV and other comorbidities in 
adults, more research is needed with young adults. 
 Finally, the most effective components of psychosocial 
treatments to use in combination with buprenorphine 
treatment are unknown.  Further research is needed to 
maximize the impact of both interventions (medical and 
psychosocial). 
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Slide 81:  Closing Exercise: “Gallery Walk” 
 
Preparation prior to the training is needed for this activity.  
 
Prior to the exercise, tape an easel pad sheet at each of 
five stations around the room, each with a question 
written on the top of the sheet. Be sure to spread them 
around the room so that no two stations are too close 
together. Use the five questions listed on slides 82 and 
83.  
  
Among the participants, form five groups and assign each 
group to one of the stations. Give each group about 5 
minutes to brainstorm and respond to the question and 
write responses on the chart paper, then ask each group 
to rotate clockwise to the next station. Let them know that 
you expect there to be overlap with regards to responses. 
Continue the process until each group arrives back to 
where they started. 
 
Slide 81 
 
 
 
Slide 82:  Closing Exercise: “Gallery Walk” 
 
The following are the first three questions: 
 Before this workshop, what were your general 
thoughts about the use of medicated-assisted 
treatment for adolescents? 
 What roadblocks or challenges do you see with 
regards to the provision of extended–care, 
medication-assisted treatment for adolescents and 
young adults addicted to opioids? 
 What are the advantages in providing medication-
assisted treatment for adolescents and young adults 
addicted to opioids? 
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Slide 83:  Closing Exercise: “Gallery Walk” 
 
The following are the final two questions: 
 What further research do you think is needed 
regarding medication-assisted treatment for 
adolescents and young adults addicted to opioids? 
 As a result of this workshop, how (if any) have your 
opinions changed regarding the use of extended–
care, medication-assisted treatment for adolescents 
and young adults addicted to opioids? 
 
When all groups have contributed to all five questions, 
ask them to rotate one more time to the station where 
they started. Ask each group to read what was added to 
their original responses. Then process the exercise by 
asking a spokesperson for each group to summarize the 
answers at each respective station. 
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Slide 84:  A Challenge to Providers from Shannon Garrett 
(Video Clip) 
 
After participating in a clinical trial on buprenorphine and 
gaining additional experience with the medication following the 
research, Shannon Garrett summarized his feelings about 
buprenorphine with a challenge to participants. 
 
Move mouse over black box. It will turn into an image of a 
hand. Click on the black box and the video will play. 
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